Form 4: ANI Pharmaceuticals CEO Nikhil Lalwani Reports Stock Transactions
SEC Form 4 Filing
Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, reports acquisition and disposal of common stock and shares withheld for tax purposes.
Summary
- Nikhil Lalwani, the President and CEO of ANI Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On February 12, 2025, Lalwani acquired 91,399 shares of common stock and 60,932 performance stock units at $0.
- On February 14, 2025, 7,799 shares were disposed of at $58.92 for tax purposes related to vesting of restricted stock.
- Following these transactions, Lalwani beneficially owns 514,910 shares of ANI Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't convey any specific positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry.
Stakeholder Impact
- Shareholders are informed about the CEO's stock transactions, providing transparency.
Key Dates
| Date | Description |
|---|---|
| 02/12/2025 | Acquisition of 91,399 shares of common stock and 60,932 performance stock units. |
| 02/14/2025 | Disposal of 7,799 shares for tax purposes at $58.92. |
| 02/18/2025 | Date of Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Stock Transactions, ANI Pharmaceuticals, Nikhil Lalwani, ANIP
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.